The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD

Abstract Mutations in the dystrophin gene ( Dmd ) result in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), which afflict many newborn boys. In 2016, Brain and Development published several interesting articles on DMD treatment with antisense oligonucleotide, kinase inhibitor,...

Full description

Saved in:
Bibliographic Details
Published in:Brain & development (Tokyo. 1979) 2017-08, Vol.39 (7), p.547-556
Main Authors: Wang, Jing-Zhang, Wu, Peng, Shi, Zhi-Min, Xu, Yan-Li, Liu, Zhi-Jun
Format: Article
Language:English
Subjects:
Adeno-associated virus vector
Animals
Becker muscular dystrophy
CRISPR-Cas Systems
CRISPR/Cas9
Dependovirus - genetics
Duchenne muscular dystrophy
Dystrophin
Dystrophin - genetics
Gene therapy
Genetic Therapy - methods
Genetic Vectors
Humans
Male
Muscular Dystrophy, Duchenne - therapy
Neurology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mutations in the dystrophin gene ( Dmd ) result in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), which afflict many newborn boys. In 2016, Brain and Development published several interesting articles on DMD treatment with antisense oligonucleotide, kinase inhibitor, and prednisolone. Even more strikingly, three articles in the issue 6271 of Science in 2016 provide new insights into gene therapy of DMD and BMD via the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9). In brief, adeno-associated virus (AAV) vectors transport guided RNAs (gRNAs) and Cas9 into mdx mouse model, gRNAs recognize the mutated Dmd exon 23 (having a stop codon), and Cas9 cut the mutated exon 23 off the Dmd gene. These manipulations restored expression of truncated but partially functional dystrophin, improved skeletal and cardiac muscle function, and increased survival of mdx mice significantly. This review concisely summarized the related advancements and discussed their primary implications in the future gene therapy of DMD, including AAV-vector selection, gRNA designing, Cas9 optimization, dystrophin-restoration efficiency, administration routes, and systemic and long-term therapeutic efficacy. Future orientations, including off-target effects, safety concerns, immune responses, precision medicine, and Dmd -editing in the brain (potentially blocked by the blood–brain barrier) were also elucidated briefly. Collectively, the AAV-mediated and RNA-guided CRISPR/Cas9 system has major superiorities compared with traditional gene therapy, and might contribute to the treatment of DMD and BMD substantially in the near future.
ISSN:0387-7604
1872-7131
DOI:10.1016/j.braindev.2017.03.024